Highly sensitive droplet digital PCR for detection of RET fusion in papillary thyroid cancer

Abstract Background Thyroid cancer is the most frequent malignancy of the endocrine system, of which papillary thyroid cancer (PTC) is the predominant form with a rapid increasing incidence worldwide. Rearranged during transfection (RET) fusions are common genetic drivers of PTC and the potent RET i...

Full description

Bibliographic Details
Main Authors: Mengke Chen, Junyu Xue, Ye Sang, Wenting Jiang, Weiman He, Shubin Hong, Weiming Lv, Haipeng Xiao, Rengyun Liu
Format: Article
Language:English
Published: BMC 2023-04-01
Series:BMC Cancer
Subjects:
Online Access:https://doi.org/10.1186/s12885-023-10852-z
_version_ 1797841038433320960
author Mengke Chen
Junyu Xue
Ye Sang
Wenting Jiang
Weiman He
Shubin Hong
Weiming Lv
Haipeng Xiao
Rengyun Liu
author_facet Mengke Chen
Junyu Xue
Ye Sang
Wenting Jiang
Weiman He
Shubin Hong
Weiming Lv
Haipeng Xiao
Rengyun Liu
author_sort Mengke Chen
collection DOAJ
description Abstract Background Thyroid cancer is the most frequent malignancy of the endocrine system, of which papillary thyroid cancer (PTC) is the predominant form with a rapid increasing incidence worldwide. Rearranged during transfection (RET) fusions are common genetic drivers of PTC and the potent RET inhibitor selpercatinib has been recently approved for treating advanced or metastatic RET fusion-positive thyroid cancer. In this study we aimed to develop a droplet digital PCR (ddPCR) system to accurately detect RET fusion in PTC samples. Methods The frequency and distribution of RET fusions in PTC were analyzed using genomic data of 402 PTC patients in The Cancer Genome Atlas (TCGA) database. To establish the ddPCR system for detecting CCDC6::RET fusion, a plasmid containing CCDC6::RET infusion fragment was constructed as standard template, the annealing temperature and concentrations of primers and probe were optimized. The analytical performance of ddPCR and quantitative reverse transcription PCR (qRT-PCR) were assessed in standard templates and tissue samples from 112 PTC patients. Sanger sequencing was performed in all the RET fusion-positive samples identified by ddPCR. Results RET fusions were observed in 25 (6.2%) of the 402 TCGA samples, and 15 (60%) of the RET fusion-positive patients had the CCDC6::RET fusion. Compared with qRT-PCR, the ddPCR method showed a lower limit of detection (128.0 and 430.7 copies/reaction for ddPCR and qRT-PCR, respectively). When applying the two methods to 112 tissue samples of PTC, eleven (9.8%) CCDC6::RET fusion-positive samples were detected by qRT-PCR, while ddPCR identified 4 additional positive samples (15/112, 13.4%). All the CCDC6::RET fusion-positive cases identified by ddPCR were confirmed by Sanger sequencing except for one case with 0.14 copies/uL of the fusion. Conclusion The accurate and sensitive ddPCR method reported here is powerful to detection CCDC6::RET fusion in PTC samples, application of this method would benefit more RET fusion-positive patients in the clinic.
first_indexed 2024-04-09T16:24:27Z
format Article
id doaj.art-d679a23b0db241c29457eb68e599f432
institution Directory Open Access Journal
issn 1471-2407
language English
last_indexed 2024-04-09T16:24:27Z
publishDate 2023-04-01
publisher BMC
record_format Article
series BMC Cancer
spelling doaj.art-d679a23b0db241c29457eb68e599f4322023-04-23T11:20:18ZengBMCBMC Cancer1471-24072023-04-012311910.1186/s12885-023-10852-zHighly sensitive droplet digital PCR for detection of RET fusion in papillary thyroid cancerMengke Chen0Junyu Xue1Ye Sang2Wenting Jiang3Weiman He4Shubin Hong5Weiming Lv6Haipeng Xiao7Rengyun Liu8Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-Sen UniversityDepartment of Endocrinology, The First Affiliated Hospital, Sun Yat-Sen UniversityInstitute of Precision Medicine, The First Affiliated Hospital, Sun Yat-Sen UniversityInstitute of Precision Medicine, The First Affiliated Hospital, Sun Yat-Sen UniversityDepartment of Endocrinology, The First Affiliated Hospital, Sun Yat-Sen UniversityDepartment of Endocrinology, The First Affiliated Hospital, Sun Yat-Sen UniversityDepartment of Breast and Thyroid Surgery, The First Affiliated Hospital, Sun Yat-Sen UniversityDepartment of Endocrinology, The First Affiliated Hospital, Sun Yat-Sen UniversityInstitute of Precision Medicine, The First Affiliated Hospital, Sun Yat-Sen UniversityAbstract Background Thyroid cancer is the most frequent malignancy of the endocrine system, of which papillary thyroid cancer (PTC) is the predominant form with a rapid increasing incidence worldwide. Rearranged during transfection (RET) fusions are common genetic drivers of PTC and the potent RET inhibitor selpercatinib has been recently approved for treating advanced or metastatic RET fusion-positive thyroid cancer. In this study we aimed to develop a droplet digital PCR (ddPCR) system to accurately detect RET fusion in PTC samples. Methods The frequency and distribution of RET fusions in PTC were analyzed using genomic data of 402 PTC patients in The Cancer Genome Atlas (TCGA) database. To establish the ddPCR system for detecting CCDC6::RET fusion, a plasmid containing CCDC6::RET infusion fragment was constructed as standard template, the annealing temperature and concentrations of primers and probe were optimized. The analytical performance of ddPCR and quantitative reverse transcription PCR (qRT-PCR) were assessed in standard templates and tissue samples from 112 PTC patients. Sanger sequencing was performed in all the RET fusion-positive samples identified by ddPCR. Results RET fusions were observed in 25 (6.2%) of the 402 TCGA samples, and 15 (60%) of the RET fusion-positive patients had the CCDC6::RET fusion. Compared with qRT-PCR, the ddPCR method showed a lower limit of detection (128.0 and 430.7 copies/reaction for ddPCR and qRT-PCR, respectively). When applying the two methods to 112 tissue samples of PTC, eleven (9.8%) CCDC6::RET fusion-positive samples were detected by qRT-PCR, while ddPCR identified 4 additional positive samples (15/112, 13.4%). All the CCDC6::RET fusion-positive cases identified by ddPCR were confirmed by Sanger sequencing except for one case with 0.14 copies/uL of the fusion. Conclusion The accurate and sensitive ddPCR method reported here is powerful to detection CCDC6::RET fusion in PTC samples, application of this method would benefit more RET fusion-positive patients in the clinic.https://doi.org/10.1186/s12885-023-10852-zRET fusionddPCRMolecular diagnosisThyroid cancer
spellingShingle Mengke Chen
Junyu Xue
Ye Sang
Wenting Jiang
Weiman He
Shubin Hong
Weiming Lv
Haipeng Xiao
Rengyun Liu
Highly sensitive droplet digital PCR for detection of RET fusion in papillary thyroid cancer
BMC Cancer
RET fusion
ddPCR
Molecular diagnosis
Thyroid cancer
title Highly sensitive droplet digital PCR for detection of RET fusion in papillary thyroid cancer
title_full Highly sensitive droplet digital PCR for detection of RET fusion in papillary thyroid cancer
title_fullStr Highly sensitive droplet digital PCR for detection of RET fusion in papillary thyroid cancer
title_full_unstemmed Highly sensitive droplet digital PCR for detection of RET fusion in papillary thyroid cancer
title_short Highly sensitive droplet digital PCR for detection of RET fusion in papillary thyroid cancer
title_sort highly sensitive droplet digital pcr for detection of ret fusion in papillary thyroid cancer
topic RET fusion
ddPCR
Molecular diagnosis
Thyroid cancer
url https://doi.org/10.1186/s12885-023-10852-z
work_keys_str_mv AT mengkechen highlysensitivedropletdigitalpcrfordetectionofretfusioninpapillarythyroidcancer
AT junyuxue highlysensitivedropletdigitalpcrfordetectionofretfusioninpapillarythyroidcancer
AT yesang highlysensitivedropletdigitalpcrfordetectionofretfusioninpapillarythyroidcancer
AT wentingjiang highlysensitivedropletdigitalpcrfordetectionofretfusioninpapillarythyroidcancer
AT weimanhe highlysensitivedropletdigitalpcrfordetectionofretfusioninpapillarythyroidcancer
AT shubinhong highlysensitivedropletdigitalpcrfordetectionofretfusioninpapillarythyroidcancer
AT weiminglv highlysensitivedropletdigitalpcrfordetectionofretfusioninpapillarythyroidcancer
AT haipengxiao highlysensitivedropletdigitalpcrfordetectionofretfusioninpapillarythyroidcancer
AT rengyunliu highlysensitivedropletdigitalpcrfordetectionofretfusioninpapillarythyroidcancer